Gp350-targeted CAR-T therapy in EBV-positive Burkitt lymphoma: pre-clinical development of gp350 CAR-T
Our findings advocate for the clinical application of gp350-directed CAR-T therapy as a prospective treatment strategy for patients with relapsed or refractory EBV-positive tumors. Given the encouraging preclinical results, further research is warranted to optimize CAR-T cell production processes and extend the potential of this therapy to other EBV-associated malignancies, paving the way for improved outcomes in affected patient populations.
Authors
- Jinjing Guo (ORCID: https://orcid.org/0009-0005-5327-1394)
- Zhimai Gao (ORCID: https://orcid.org/0009-0005-3633-5173)
- Yangyang Ding (ORCID: https://orcid.org/0000-0003-1588-2571)
- Liang Xue (ORCID: https://orcid.org/0000-0003-3606-4615)
- Feng-Ya Nan
- Tielin Zhou
- Yan Li (ORCID: https://orcid.org/0000-0003-3901-0727)
- Fan Wu (ORCID: https://orcid.org/0000-0003-1039-3752)
- Jiajia Wang (ORCID: https://orcid.org/0000-0002-0897-8033)
- Yanli Li (ORCID: https://orcid.org/0000-0002-5722-7375)
- Zhimin Zhai
- Meng Xiao (ORCID: https://orcid.org/0000-0003-4761-7756)
- Huiping Wang (ORCID: https://orcid.org/0000-0003-3733-7638)
- Na Cao (ORCID: https://orcid.org/0009-0000-9628-7074)
- Cong Li (ORCID: https://orcid.org/0000-0003-4420-8623)
Institutions
- Anhui Medical University (CN)
- Fuyang City People's Hospital (CN)
- The People's Hospital Tongling (CN)
- Fuyang Maternity and Child Health Care Hospital (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Jining First People's Hospital (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
- Fuyang Second People's Hospital (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-02-10
- DOI
- https://doi.org/10.1186/s12967-025-06188-w
- Citations
- 5
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- National Natural Science Foundation of China